Who makes Anagre Cap.?

Anagre Cap. is developed by Yuhan Corporation.

What development phase is Anagre Cap. in?

Anagre Cap. is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Anagre Cap.

Yuhan Corporation · FDA-approved active Small molecule Quality 0/100

Anagrelide, marketed by Yuhan Corporation, is an established drug in the market with a key composition patent expiring in 2028. Its primary strength lies in its current market presence and revenue generation, though specific figures are not disclosed. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Anagre Cap.
Sponsor	Yuhan Corporation
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Anagre Cap. in Patients With High-Risk Essential Thrombocythemia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Anagre Cap. CI brief — competitive landscape report
Anagre Cap. updates RSS · CI watch RSS
Yuhan Corporation portfolio CI